Bellevue Group AG Decreases Stock Holdings in Cencora, Inc. (NYSE:COR)

Bellevue Group AG lessened its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 19.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 72,053 shares of the company's stock after selling 17,276 shares during the quarter. Bellevue Group AG's holdings in Cencora were worth $16,218,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Pacer Advisors Inc. boosted its position in Cencora by 6,855.3% in the third quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company's stock valued at $464,874,000 after buying an additional 2,035,679 shares in the last quarter. Legal & General Group Plc lifted its holdings in Cencora by 3.7% in the second quarter. Legal & General Group Plc now owns 1,875,445 shares of the company's stock valued at $422,538,000 after buying an additional 67,287 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Cencora by 1.2% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,552,213 shares of the company's stock worth $349,372,000 after buying an additional 18,782 shares during the last quarter. Swedbank AB grew its holdings in shares of Cencora by 2.3% in the 3rd quarter. Swedbank AB now owns 1,394,449 shares of the company's stock valued at $313,863,000 after buying an additional 31,104 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in Cencora by 10.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,262,882 shares of the company's stock worth $284,544,000 after acquiring an additional 119,927 shares during the last quarter. Institutional investors own 97.52% of the company's stock.

Cencora Trading Up 0.7 %

Shares of COR traded up $1.86 during trading hours on Friday, hitting $251.55. The company had a trading volume of 1,103,278 shares, compared to its average volume of 1,241,715. The stock's 50 day moving average price is $234.91 and its 200 day moving average price is $232.53. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. Cencora, Inc. has a 52-week low of $195.83 and a 52-week high of $253.27. The firm has a market cap of $49.57 billion, a P/E ratio of 33.50, a P/E/G ratio of 1.67 and a beta of 0.44.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.87%. This is a boost from Cencora's previous quarterly dividend of $0.51. The ex-dividend date of this dividend was Friday, November 15th. Cencora's payout ratio is presently 29.29%.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 50,000 shares of the company's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the sale, the chairman now owns 326,557 shares in the company, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 93,018 shares of company stock valued at $22,478,942 in the last three months. 15.80% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Evercore ISI raised their price target on Cencora from $250.00 to $285.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. StockNews.com cut shares of Cencora from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 20th. JPMorgan Chase & Co. upped their target price on Cencora from $280.00 to $287.00 and gave the company an "overweight" rating in a research report on Wednesday, August 21st. Bank of America restated a "neutral" rating and set a $245.00 target price (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Finally, Barclays lifted their price target on shares of Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, Cencora presently has a consensus rating of "Moderate Buy" and a consensus price target of $271.20.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.